Optimization and in vivo evaluation of innovative theranostic imaging probes using Anticalin and PASylation technologies (A08)

• Subject Area: Nuclear Medicine, Radiotherapy, Radiobiology
• Term: from 2013 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618

Within the new funding period, Project A8 will focus on the development and preclinical evaluation of novel imaging probes such as Anticalins, Fab fragments and other binding proteins as well as bifunctional fusion proteins for pretargeting radio-immuno therapy and diagnostics. Using state of the art protein design concepts, we will apply innovative methods for protein radiolabeling and plasma half-life optimization. Oncologically relevant targets such as the established cell surface receptors/proteins HER2, CEA, PSMA, ED-B, PD-L1 as well as tumor-specific sugars will be addressed in this project.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
• Major Instrumentation: Field-flow Fractionation
• Applicant Institution: Technische Universität München (TUM)
• Project Heads: Claudia Mendler; Professor Dr. Markus Schwaiger; Professor Arne Skerra, Ph.D.